Itopride in the treatment of functional dyspepsia in Chinese patients: A prospective, multicentre, post-marketing observational study

Clinical Drug Investigation

Volumn 31, Issue 12, 2011, Pages 865-875

  Sun, Jing ^a   Yuan, Yao Zong ^a   Holtmann, Gerald ^b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Gastrokinetics; Itopride; Non ulcer dyspepsia; Postmarketing surveillance.

Indexed keywords

ITOPRIDE;

ABDOMINAL PAIN; ADULT; CHINESE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; FUNCTIONAL DYSPEPSIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MULTICENTER STUDY; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RELAPSE; REVIEW; TOTAL SYMPTOM SCORE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAMIDES; BENZYL COMPOUNDS; CHINA; DRUG ADMINISTRATION SCHEDULE; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80155126037     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11593290-000000000-00000     Document Type: Review

References (33)

1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79
2. Mansi C, Mela GS, Pasini D, et al. Patterns of dyspepsia in patients with no clinical evidence of organic diseases. Dig Dis Sci 1990; 1452-8
3. Johnsen R, Bernersen B, Straume B, et al. Prevalence of endoscopic and histological findings in subjects with and without dyspepsia. BMJ 1991; 302: 749-52
4. Klauser AG, Voderholzer WA, Knesewitsch PA, et al. What is behind dyspepsia?. Dig Dis Sci 1993; 38: 147-54 (Pubitemid 23039467)
5. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-55 (Pubitemid 39345892)
6. Feinle-Bisset C, Vozzo R, Horowitz M, et al. Diet, food intake, and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia. Am J Gastroenterol 2004; 99: 170-81 (Pubitemid 38679120)
7. Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solidphase gastric emptying in functional dyspepsia: a metaanalysis. Dig Dis Sci 1998; 43: 2028-33
8. Miyoshi A, Masamime O, Sekiguchi T, et al. Clinical evaluation of itopride hydrochloride for gastrointestinal symptoms associated with chronic gastritis: a multicentre double blind clinical trial using cisapride as control drug. Clin Pharmacol Ther 1994; 4: 261-79
9. Inoue K, Sanada Y, Fujimura J, et al. Effect of itopride hydrochloride on the digestive symptoms of chronic gastritis with reflux esophagitis. Clin Med 1999; 15: 1803-9
10. Shenoy KT, Veenasree , Leena KB. Efficacy and tolerability of itopride hydrochloride in patients with non-ulcer dyspepsia. J Indian Med Assoc 2003; 101: 387-8 (Pubitemid 37237101)
11. Ke MY, Liu XH, Xu DB, et al. Itopride treatment on chronic gastritis with dyspepsia symptoms: a multicenter, randomized, double-blind, parallel- and placebo-controlled study. Chin J Med Guide 2003; 5: 79-81
12. Holtmann G, Talley NJ, Liebregts T, et al. A placebo controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 832-40 (Pubitemid 43290921)
13. Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007; 22: 304-10 (Pubitemid 46238756)
14. Drossman DA, editor. Rome III: the functional gastrointestinal disorders. 3rd ed. McLean (VA): Degnon Associates; 2006
15. Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 2006; 41: 513-23 (Pubitemid 44138192)
16. Jolliet P, Nion S, Allain-Veyrac G, et al. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacological Research 2007; 56: 11-7 (Pubitemid 46990926)
17. Reddymasu SC, Soykan I, McCallum RW, et al. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007; 102: 2036-45 (Pubitemid 47301500)
18. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-70
19. Mushiroda T, Douya R, Takahara E, et al. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos 2000; 28 (10): 1231-7
20. Ohki R, TakahashiM,Mizuno O, et al. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing Clin Electrophysiol 2001; 24 (1): 119-21 (Pubitemid 32165740)
21. Endo J, Nomura M, Morishita S, et al. Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography. J Gastroenterol 2002; 37: 888-95 (Pubitemid 35423040)
22. Xu DB, Ke MY. Itopride hydrochloride, a new gastrointestinal prokinetic agent. Chin J New Drug 2002; 11 (6): 449-51
23. Sawant P, Das HS, Desai N, et al. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. JAPI 2004; 52: 626-8 (Pubitemid 41279707)
24. Gupta S, Kapoor V, Gupta BM, et al. Effect of itopride hydrochloride on QT interval in adult healthy volunteers. JK-Practitioner 2005; 12: 207-10 (Pubitemid 41727252)
25. Ganaton Post Marketing Surveillance Study Group. Post marketing surveillance study to evaluate the efficacy and safety of Ganaton- (itopride hydrochloride) in the management of functional dyspepsia. JAMA 2004; 3 (4): 69-74
26. Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57 (6): 740-6 (Pubitemid 351716964)
27. Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther 2006; 24: 475-92 (Pubitemid 44051323)
28. Sumil K, Tari A, Kajiyama G, et al. Clinical effects of itopride hydrochloride on symptoms accompanied with chronic gastritis. Medical Consultation and New Remedies 1993; 30 (11): 2133-40
29. Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992; 305: 748-9
30. Corsetti M, Caenepeel P, Fischler B, et al. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol 2004; 99: 1152-9 (Pubitemid 38917823)
31. Cremonini F, Talley NJ. The overlap between functional dyspepsia and irritable bowel syndrome-a tale of one or two disorders?. Aliment Pharmacol Ther 2004; 20 (Suppl. 7): 40-9 (Pubitemid 39657675)
32. Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities?. Best Pract Res Clin Gastroenterol 2004; 18: 695-706 (Pubitemid 39157844)
33. Locke III GR, Weaver AL, Melton III LJ, et al. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol 2004; 99: 350-7 (Pubitemid 38279880)